Latest Conference

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Dr Jonathan Meyer highlights effective VMAT 2 inhibitors for tardive dyskinesia treatment, emphasizing tailored approaches for improved patient outcomes.

Innovative approaches enhance understanding of tardive dyskinesia's impact on patients' lives, shifting focus from detection to functional well-being.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

Clinician discusses the importance of maximizing medication doses and trial periods for effectively managing tardive dyskinesia at the Southern California Psychiatry Conference.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.

Yvette Elpidio, PMHNP-BC, shares insights on NMDA agonists at the Southern California Psychiatry conference.

Deb York, PMHNP-BC, sheds light on postpartum psychiatry at the conference.

The Chair of the Southern California Psychiatry Conference offers his favorite take home points on schizophrenia and M1-M4 agonists that can be found in the initial sessions.

Brush up on your reading before you attend the Southern California Psychiatry Conference!

An interdisciplinary gathering at the 2025 virtual conference of the Society for Digital Mental Health heard presentations and panel discussions on digital therapeutics, along with reports of studies on the technology and outcomes by student and young researchers.

Discover key insights from the APA Annual Meeting, highlighting advancements in lifestyle psychiatry, ADHD treatment, and innovative suicide prevention models.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

How do psychiatrists feel about the current polycrises? “Overwhelmed.”

Vincenzo Di Nicola discusses the importance of pluralism in social psychiatry and the need for culturally relevant psychotherapy at the 2025 APA Annual Meeting.

Psychiatrists united in Los Angeles for a rally, advocating for mental health funding amidst growing concerns over service cuts and societal challenges.

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

How many apps do you use on your phone? John Luo, MD, a technology expert shares his thoughts on their usefulness at the 2025 APA Annual Meeting.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

Psychiatry must embrace media to combat misinformation, shared Mena Mirhom, MD, FAPA, at the 2025 APA Annual Meeting.

Will AI replace psychiatrists and mental health clinicians? John Luo, MD, thinks not, despite the many technological advances of today.